In principle, leveraging OVs to deliver PD-1/PD-L1 ICIs preferentially to tumor tissues is a rational approach since the immunogenic nature of OVs should also prime the TME to potentiate ICI-induced anti-tumor responses. This evidence concerns the gene CD274 and neoplasm.